UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000000920
Receipt number R000001014
Scientific Title Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer
Date of disclosure of the study information 2007/12/02
Last modified on 2015/06/14 12:51:31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer

Acronym

Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer

Scientific Title

Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer

Scientific Title:Acronym

Feasibility study of adjuvant therapy with S-1 plus CDDP in gastric cancer

Region

Japan


Condition

Condition

Gastric cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To confirm the feasibility and safety of adjuvant treatment with a combination of S-1 plus CDDP in patients with gastric cancer.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Treatment compliance with 3 courses of S-1 plus CDDP

Key secondary outcomes

Treatment compliance with 2 courses of S-1 plus CDDP, proportion of patients receiving treatment according to protocol, and adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Adjuvant chemotherapy (S-1 monotherapy followed by S-1+CDDP therapy followed by S-1 monotherapy)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Histologically proved adenocarcinoma of stomach
2) >=D2 lymph node dissection, curability B
3) Stage IIIA/IIIB (Japanese classification)
4) ECOG performance status 0-1
5) Age between 20 and 75 years
6) No prior chemotherapy or radiotherapy
7) Able to be enrolled between 4 and 6 weeks after surgery
8) Enough oral food intake possible between 4 and 6 weeks after surgery
9) Adequate organ function
10) Written informed consent

Key exclusion criteria

1)synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ
2)pregnant or breast-feeding women
3)severe mental disease
4)systemic administration of corticosteroids, flucytosine, phenytoin or warfarin
5)other severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis)
6)myocardial infarction within the past 6 months
7)Inadequate physical condition, as diagnosed by primary physician

Target sample size

63


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tetsuya Hamaguchi

Organization

National Cancer Center Hospital

Division name

Gastrointestinal Oncology

Zip code


Address

5-1-1 Tsukiji, Chuo-ku, Tokyo

TEL

03-3542-2511

Email

thamaguc@ncc.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Daisuke Takahari

Organization

Aichi Cancer Center Hospital

Division name

Medical Oncology

Zip code


Address

1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi

TEL

052-762-6111

Homepage URL


Email

dtakahari@aichi-cc.jp


Sponsor or person

Institute

National Cancer Center Hospital

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2007 Year 12 Month 02 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications

http://dx.doi.org/10.1007/s00280-010-1432-8

Number of participants that the trial has enrolled


Results

A total of 63 enrolled patients have been evaluated. Grade 3/4 toxicities included neutropenia (40%), anorexia (28%), and febrile neutropenia (4%) before protocol amendment (n = 25), and neutropenia (37%), anorexia (8%), and febrile neutropenia (3%) after amendment implementation (n = 38). Excluding ineligible cases, treatment completion rates were 57% (12/21) before and 81% (30/37) after the protocol amendment.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2007 Year 08 Month 21 Day

Date of IRB


Anticipated trial start date

2007 Year 09 Month 01 Day

Last follow-up date

2010 Year 09 Month 01 Day

Date of closure to data entry


Date trial data considered complete

2015 Year 09 Month 30 Day

Date analysis concluded

2015 Year 09 Month 30 Day


Other

Other related information

We undergo 5 year survival analysis.


Management information

Registered date

2007 Year 12 Month 02 Day

Last modified on

2015 Year 06 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001014


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name